Mergers & Acquisitions - Biotechnology

Filter

Current filters:

Biotechnology

Popular Filters

126 to 150 of 258 results

Tranzyme exploring options, including sale of the firm; is Ache up for sale?

11-02-2013

Following two recent R&D pipeline disappointments, the board of directors of US biotech firm Tranzyme…

Ache Laboratorios FarmaceuticosBiotechnologyMergers & AcquisitionsNorth AmericaPharmaceuticalSouth AmericaTranzyme

Elan sells its Tysabri rights to Biogen; posts 2012 financials

07-02-2013

Ireland-based drugmaker Elan Corp (NYSE: ELN) said yesterday that partner US biotech firm Biogen Idec…

Biogen IdecBiotechnologyElanFinancialMergers & AcquisitionsNeurologicalPharmaceuticalTysabri

Zoetis IPO caps strong month for life sciences financings, says Burrill & Co

04-02-2013

Life sciences financing activity got a strong start in the New Year as companies raised $10.3 billion…

AllerganBiotechnologyFinancialMAP PharmaceuticalsMergers & AcquisitionsPfizerPharmaceuticalZoetis

Progenics buys Molecular Insight Pharma to expand oncology pipeline

23-01-2013

USA-based Progenics Pharmaceuticals (Nasdaq: PGNX) revealed yesterday that it has acquired Molecular…

AzedraBiotechnologyMergers & AcquisitionsMolecular Insight PharmaceuticalsOncologyProgenics PharmaceuticalsTrofex

Health care M&A spending falls nearly 40% in 2012, lowest year on record since 2003; report

22-01-2013

In 2012, dealmakers committed $143.3 billion to finance the year's activity in the health care merger,…

BiotechnologyGlobalMergers & AcquisitionsPharmaceutical

Pfizer's Zoetis spin-off could raise $12 billion; BGI-Shenzhen updates on Complete Genomics deal

20-01-2013

Pfizer (NYSE: PFE), the world's largest drugmaker by sales, which has previously said it is spinning…

BGI-ShenzhenBiotechnologyComplete GenomicsFinancialMergers & AcquisitionsPfizerPharmaceuticalZoetis

Oculus Innovative Sciences plan to spin off biotechnology business

13-01-2013

USA-based health care company Oculus Innovative Sciences (Nasdaq: OCLS) last week announced that its…

BiotechnologyMergers & AcquisitionsMicrocynOculus Innovative SciencesRUT58-60Ruthigen

2012 again a bumper year for Pharma M&A, but values well down

09-01-2013

The year 2012 was again a bumper year for merger and acquisition activity in the global pharmaceutical,…

BiotechBiotechnologyGenericsMergers & AcquisitionsPharmaceutical

Shire to acquire Lotus Tissue Repair for undisclosed price

09-01-2013

Ireland-headquartered drugmaker Shire (LSE: SHP) said yesterday that it has signed an agreement to acquire…

BiotechnologyLotus Tissue RepairMergers & AcquisitionsPharmaceuticalRare diseasesShire

Big pharma will increasingly tap M&A to close $100 billion growth gap

07-01-2013

Big pharma companies are facing a widening "growth gap" that will increase pressure to drive growth through…

BiotechnologyFinancialMergers & AcquisitionsPharmaceutical

Pharmaceutical M&A deals in 2012

07-01-2013

Details for the 131 M&A announcements in 2012 recorded by The Pharma Letter are provided in the full…

BiotechGenericsMergers & AcquisitionsPharmaceutical

Evotec acquires Cell Culture Service GmbH; expands deal with AstraZeneca

07-01-2013

German biotech firm Evotec (EVT: TecDAX) has acquired all the shares in Cell Culture Service GmbH (CCS),…

AstraZenecaBiotechnologyCell Culture Service GmbHDiabetesEvotecLicensingMedImmuneMergers & AcquisitionsPharmaceutical

Questcor Pharmaceuticals to acquire BioVectra for around $50 million

04-01-2013

California, USA-based Questcor Pharmaceuticals (Nasdaq: QCOR) has signed a definitive agreement to acquire…

BiotechnologyBioVectraGenericsMergers & AcquisitionsPharmaceuticalProductionQuestor Pharmaceuticals

American Capital commits $212 million to acquire Cambridge Major Laboratories

03-01-2013

Private equity firm American Capital (Nasdaq: ACAS) says that it has committed $212 million in the buyout…

American CapitalBiotechnologyCambridge Major LaboratoriesGenericsMergers & AcquisitionsPharmaceutical

Vivalis and Intercell announce "merger of equals"

18-12-2012

French biotech firm Vivalis (Euronext: VLS) has entered into an accord to acquire Intercell (ICEL.VI)…

BiotechnologyIntercellMergers & AcquisitionsVaccinesValnevaVivalis

Enzon mulls sale of company; Bio-Rad to acquire business from MorphoSys

18-12-2012

USA-based Enzon Pharmaceuticals (Nasdaq: ENZN) said yesterday that its board has retained Lazard to act…

Bio-Rad LaboratoriesBiotechnologyEnzon PharmaceuticalsMergers & AcquisitionsMorphoSys

126 to 150 of 258 results

Back to top